Gefitinib

CHICAGO — Platinum-doublet chemotherapy did not extend survival for patients with advanced nonsquamous non-small cell lung cancer who responded to EGFR tyrosine kinase inhibitor therapy, according to randomized phase 3 study results.

Adjuvant gefitinib may be a reasonable alternative to standard-of-care chemotherapy for patients with EGFR-positive stage II or stage IIIA non-small cell lung cancer, according to study results published in Journal of Clinical Oncology.

In the first-line setting, osimertinib and gefitinib as combination therapy for the treatment of EGFR-mutated non-small cell lung cancer is tolerable, according to findings presented at the virtual ASCO annual meeting.

Gefitinib administered concurrently with carboplatin plus pemetrexed improved PFS compared with gefitinib alone among patients with untreated advanced non-small cell lung cancer with EGFR mutations, according to results of the randomized phase 3 NEJ009 trial published in Journal of Clinical Oncology.

First-line osimertinib improved OS compared with standard-of-care epidermal growth factor receptor tyrosine kinase inhibitors among patients with previously untreated advanced EGFR-mutated non-small cell lung cancer, according to results from the randomized phase 3 FLAURA trial presented at European Society for Medical Oncology Asia Congress and simultaneously published in The New England Journal of Medicine.

The addition of pemetrexed and carboplatin chemotherapy to gefitinib significantly extended PFS and OS for patients with advanced non-small cell lung cancer and EGFR-sensitizing mutations, according to results of a randomized phase 3 study published in Journal of Clinical Oncology.

The addition of metformin hydrochloride to standard epidermal growth factor receptor tyrosine kinase inhibitors significantly improved PFS and OS among patients with advanced EGFR-mutated lung adenocarcinoma, according to randomized phase 2 study results published in JAMA Oncology.

Osimertinib significantly prolonged OS compared with previous standard-of-care first-line therapies for patients with locally advanced or metastatic, EGFR-mutated non-small cell lung cancer, according to the agent’s manufacturer.